doi:10.1515/hmbci-2020-0055
Over a decade of use, cumulative costs reach $800-2,400 CAD for generic products
Youve already got a whole population of compounders out there that are making it, the product quality is adequate, people are using it, and then youre suddenly going to take it away
[PMID: 6658827] PubMed record related to this compound for laboratory literature review
#DrugInteractionSeries #ClinicalPharmacy #PharmD #MedicationSafety #PatientSafety #Nephrology #DrugSafety To view or add a comment, sign in Clozapine Explore how tailored modifications of Clozapine can curb its notorious side effects while preserving therapeutic potency
GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034